|
|
| OCs Reduce Risk of Ovarian Cancer in |
|
| High-Risk
Women |
|
|
|
|
|
|
|
|
|
|
|
|
|
| n | BRCA1
and BRCA2 mutations increase ovarian |
||||||||||
| cancer risk |
|||||||||||
| n | 45% increased
risk in carriers of BRCA 1 |
||||||||||
| n | 25% increased
risk in carriers of BRCA 2 |
||||||||||
| n | OCs reduce
ovarian cancer risk in carriers |
||||||||||
| of BRCA1
or BRCA2 |
|||||||||||
| n | 20% reduction
with short-term OC use (3 y) |
||||||||||
| n | 60% reduction
with long-term OC use (6 y) |
||||||||||
| Narod SA et al. N Engl
J Med. 1998;339:424-428. |
